Transgene advances its myvac platform into NSCLC with TG4070, signaling commercial expansion for individualized neoantigen vaccines.The Manila Times
Concurrently, new research highlights critical data leakage in pMHC prediction benchmarks, demonstrating that generalization to unseen alleles is significantly lower than conventional metrics suggest.bioRxiv
A new study in Nature evaluates neoantigen vaccine responses using mechanistic and model-based frameworks. This work provides a structured approach to assessing clinical efficacy, offering investors and developers clearer methodologies for validating therapeutic outcomes.
Researchers demonstrate that reported peptide-MHC (pMHC) AUROCs of 0.85-0.95 overstate generalization due to data leakage from dense immunopeptidome data on well-studied alleles. Using a harmonized corpus of 5.8 million measurements, they show true generalization to unseen alleles is in the high 0.7s. They released an open benchmark and a new predictor that outperforms eight existing models by +0.22 to +0.37 AUROC on least-studied genes.
Transgene is expanding its myvac platform into non-small cell lung cancer (NSCLC) with TG4070, an individualized neoantigen therapeutic vaccine. This move marks a commercial progression for the company’s personalized vaccine approach beyond previous indications.